Based on recent developments with blue light cystoscopy, the use of white light cystoscopy alone is now considered suboptimal as a diagnostic tool.
Biopsy decreases overall uncertainty, is safe, fairly accurate, relatively inexpensive, and improves shared decision-making with patients.
More evidence is needed before blue light cystoscopy becomes the standard of care for diagnosis and treatment and renders white light cystoscopy obsolete.
The oral beta-3 agonist vibegron, taken once daily at either 50 mg or 100 mg, is well tolerated and results in clinically and statistically significant reductions in daily micturitions, urge incontinence, and urgency episodes.
Renal mass biopsy provides actionable information, but only under specific circumstances—yet it is an increasingly necessary part of the nuanced patient discussion.
A nickel-sized leadless titanium device, implanted in patients’ ankles, could provide years of relief from overactive bladder syndrome.
There were significant improvements among those studied on the higher radiation dose in terms of biochemical failure and distant metastases, however.
Practicing urologists should consider the potential value of performing a multiparametric MRI for a biopsy in men with suspected prostate cancer based on results from the PRECISION trial, says Veeru Kasivisvanathan, MRCS.
Urologists can claim substantial victories as a result of the Bipartisan Budget Act of 2018, signed into law by President Trump in February—including an end to the Independent Payment Advisory Board, which had been established by the Affordable Care Act to help control Medicare spending.